Veloxity Labs acquires Sciex's accurate mass spectrometer, ZenoTOF 8600 System

US-based Veloxity Labs, a bioanalytical CRO built for programmes that need speed with purpose, has announced the acquisition of the ZenoTOF 8600 system from Sciex, a global leader in life science analytical technologies.

Veloxity is the first bioanalytical CRO in the United States to acquire this new accurate mass spectrometer, with delivery expected later this year and installation/qualification starting January of 2026.

With this acquisition, Veloxity is expanding its toolkit for peptide and protein bioanalysis—strengthening method development speed, identity confirmation and interference resolution—while complementing its existing LC–MS/MS (triple quadrupole) platforms.

The ZenoTOF 8600 system investment is a key part of Veloxity’s continued lab expansion, with expectations of adding an additional instrument lab, increased freezer storage and room for team growth later this year. This facility growth signals long-term stability and near-term capacity for sponsors planning GLP-enabling and Phase 1/2 work.

“Adding the ZenoTOF 8600 system gives our scientists a faster, more selective way to solve hard problems, especially in peptide and complex matrix workflows,” noted Shane Needham, PhD, Co-Founder, President & CEO, Veloxity Labs. “We’re investing in innovation that will create an immediate impact on sponsor timelines: quicker method cycles, better tools to handle interferences and added sensitivity headroom for GLP-1 receptor agonists and other peptides. It’s a natural fit with our model of speed with purpose and our growth in capacity.”